Serveur d'exploration Tocilizumab

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Eléments de l'association

Japon44
Atsushi Kawakami5
Japon Sauf Atsushi Kawakami" 40
Atsushi Kawakami Sauf Japon" 1
Japon Et Atsushi Kawakami 4
Japon Ou Atsushi Kawakami 45
Corpus638
\n\n\n\n \n

List of bibliographic references

Number of relevant bibliographic references: 4.
Ident.Authors (with country if any)Title
000021 Jumpei Temmoku [Japon] ; Yuya Fujita [Japon] ; Naoki Matsuoka [Japon] ; Takeshi Urano [Japon] ; Makiko Yashiro Furuya [Japon] ; Tomoyuki Asano [Japon] ; Shuzo Sato [Japon] ; Haruki Matsumoto [Japon] ; Hiroshi Watanabe [Japon] ; Hideko Kozuru [Japon] ; Hiroshi Yatsuhashi [Japon] ; Atsushi Kawakami [Japon] ; Kiyoshi Migita [Japon]Uric acid-mediated inflammasome activation in IL-6 primed innate immune cells is regulated by baricitinib.
000168 Tsutomu Takeuchi [Japon] ; Yoshiya Tanaka [Japon] ; Sakae Tanaka [Japon] ; Atsushi Kawakami [Japon] ; Yeong-Wook Song [Corée du Sud] ; Yi-Hsing Chen [Taïwan] ; Mitsuhiro Rokuda [Japon] ; Hiroyuki Izutsu [Japon] ; Satoshi Ushijima [Japon] ; Yuichiro Kaneko [Japon] ; Yoshihiro Nakashima [Japon] ; Teruaki Shiomi [Japon] ; Emi Yamada [Japon]Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
000298 Yoshikazu Nakaoka ; Mitsuaki Isobe ; Yoshiya Tanaka ; Tomonori Ishii ; Seido Ooka ; Hiroaki Niiro [Japon] ; Naoto Tamura ; Shogo Banno ; Hajime Yoshifuji [Japon] ; Yasushi Sakata ; Atsushi Kawakami ; Tatsuya Atsumi ; Shunsuke Furuta ; Hitoshi Kohsaka ; Katsuya Suzuki ; Ryoki Hara ; Yasuhiro Maejima ; Hiroshi Tsukamoto ; Yoshinari Takasaki ; Katsuhisa Yamashita ; Norihiro Okada ; Shinji Yamakido ; Syuji Takei ; Shumpei Yokota [Japon] ; Norihiro Nishimoto [Japon]Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.
000586 Tomohiro Koga ; Naoko Hagimori [Japon] ; Shuntaro Sato [Japon] ; Shinpei Morimoto [Japon] ; Naoki Hosogaya [Japon] ; Chizu Fukushima [Japon] ; Hiroshi Yamamoto [Japon] ; Atsushi KawakamiAn open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021